Glenmark Pharmaceuticals Reports Multi-Fold Rise in Q1 Profit and Revenue
Glenmark Pharmaceuticals reported a significant rise in consolidated profit after tax to Rs 482.83 crore for Q1 ending June 30, 2026, up from Rs 46.97 crore the previous year, aided by strong revenue growth and a low base effect. Total revenue increased to Rs 4,018.48 crore from Rs 3,264.44 crore, with higher expenses of Rs 3,440.86 crore. Growth was driven by strong performance in India, North America, and Emerging Markets, supported by new respiratory product launches and a diversified global business strategy.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 38/100.
Outlets measured: businessstandard, businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 31 Jul, 02:16 pm. Other outlets followed.